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ABSTRACT OF THE THESIS 
 
Perivascular Stem Cells Induce Paracrine-mediated Osteogenesis  
via Upregulation of Secretory Wnt-related Proteins 
 
by  
 
Gregory Asatrian 
Master of Science in Oral Biology 
University of California, Los Angeles, 2018 
Professor Kang Ting, Chair  
 
With an increase in the number of annual craniomaxillofacial orthopaedic procedures being 
performed, and an understanding of the drawbacks of autologous bone grafting, the bone graft 
substitute market is burgeoning. Several bone graft alternatives, including, FDA-approved 
osteogenic molecule, Bone Morphogenetic Protein-2 have shown promise in promoting large 
volumes of de novo bone formation, however are ladened with several adverse effects, hampering 
their clinical application. Perivascular Stem Cells (PSC) are a prospectively purified mesenchymal 
stem cell population isolated from adipose tissue by fluorescent-activated cell sorting (FACS), and 
have previously been shown to induce robust bone formation in small and large animal models. 
Herein, by utilizing species-specific MHC immunohistochemistry, we demonstrated that PSC 
elicit their osteogenic effect primarily via a paracrine-mediate mechanism. Subsequently, after 
resolving that PSC mediate host mesenchymal stem cells, via the secretion of pro-osteogenic 
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molecules, RNA sequencing was performed to compare PSC with their unpurified predecessor, 
stromal vascular fraction (SVF). It was observed that Wnt-related secretory molecules, WISP-1 
and Wnt16 were upregulated in PSC by 72- and 21- fold, respectively, when compared to SVF. 
Gain-of-function assays for these two secretory molecules revealed a significant increase in 
osteogenic markers, whereby a significant decrease in osteogenic markers was observed when 
WISP-1 or Wnt16 were knocked-down in PSC. Wnt16 was observed to indeed be a mixed ligand 
and demonstrate activation of both the canonical and noncanonical Wnt pathways. In aggregate, 
these data demonstrate that PSC promote osteogenesis via a primarily paracrine-mediate secretion 
of pro-osteogenic molecules, of which WISP-1 and Wnt16 are highly upregulated and play a 
functional and necessary role in PSC osteogenesis. 
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Significance Statement 
With an increase in the number craniomaxillofacial orthopaedic procedures being 
performed per annum, and the improvements in the scientific and medical understanding of the 
drawbacks of autologous bone grafting, the bone graft substitute market is burgeoning. 
Perivascular Stem Cells (PSC) are a novel, prospectively purified, autologous mesenchymal stem 
cell population isolated from adipose tissue by fluorescent-activated cell sorting (FACS). Our 
previous studies have demonstrated that PSC induce robust bone formation in large and small 
animal models. Until present, a paucity existed regarding the underlying mechanism by which this 
improved bone formation occurred. Herein, we demonstrate the, primarily, paracrine-mediated 
osteogenic effect of PSC, via upregulation of secretory molecules WISP-1 and Wnt16, and their 
downstream canonical and noncanonical Wnt pathway activations. By understanding the 
mechanism by which PSC mediate bone formation, we can optimize and safely transition these 
findings to future craniofacial patient care. 
 
Introduction 
With over 2.2 million surgeries performed annually, non-healing skeletal defects are 
addressed in the diverse fields of orthopedic, plastic, and oral surgery 1, 2. Several modalities of 
bone regeneration are present in the surgeons’ armamentarium, however, most are ladened with 
significant disadvantages, hampering their clinical application. Autologous bone grafting, 
frequently isolated from the iliac crest, is still the gold standard for grafting3, however is 
encumbered by several significant draw backs including donor site morbidity4-6, associated 
complications from an increased operating time and additional surgical site, and a finite autologous 
supply.  
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Due to these limitations, investigators sought alternative bone graft substitutes, including, 
but not limited to, one of the most commonly studied and utilized growth factor, Bone 
Morphogenetic Protein (BMP)-2. BMP-2 is indeed a U.S. Food and Drug Administration (FDA)-
approved osteoinductive growth factor, and has repeatedly been shown to induce robust and 
abundant bone formation7, 8. Current studies and clinical correlates, however, have demonstrated 
the species-specific dosing response with BMP-2, and a necessary increase in dose concentration 
with increasing phylogenetic complexity9. With this necessary increase in clinical concentration, 
BMP-2 was observed and confirmed to elicit a number of adverse effects including heterotopic 
bone formation10-15, late-osteoclast activation16-18, cystic bone formation 18-20, and post-operative 
inflammation21-24. 
Another alternative to bone grafting was the utilization of autologous mesenchymal stem 
cell (MSC). MSC can accelerate bone regeneration by several mechanisms, including direct bone 
formation, recruitment and activation of osteoprogenitor cells, immunomodulation, and the 
promotion of vascularization to the site of implantation 25. Such mesenchymal stem cells can be 
harvested from various loci and isolated by several modalities, each of which have several 
positives attributes, but, again, are outweighed by significant drawbacks (reviewed by Asatrian, et 
al 26).  
The most frequently studied are those MSC isolated from the bone marrow, BMSC27-29. 
BMSC, although possess multi-lineage potential, including potent osteogenic potential30-32, 
possess similar drawbacks as autologous bone isolation from the iliac crest, including morbidity 
and complications of isolation from the hip33. Furthermore, BMSC are limited in supply and 
require several passages of in vitro expansion34, which reduces cellular activity and increases risk 
of mutations and corresponding immunogenic response35, 36.   
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Another site of MSC isolation that was discovered in 2001 by Zuk et al, was adipose 
tissue37. Adipose-derived stem cells or stromal cells (ASC) have been studied extensively since 
their advent due to their abundance in supply and relative ease if harvest via routine liposuction 
procedures. Subsequent to harvest, lipoaspirates are immediately treated with collagenase, 
yielding a mixed cell homogenate termed the stromal vascular fraction (SVF). This SVF contains 
ASC in addition to a mixed population of endothelial, hematopoetic and stromal cells 38, 39. 
Purification markers vary from study to study; however, most investigators agree to isolate ASC 
from SVF via expression of cell markers CD73, CD90, CD44, and CD940. Despite the fact that 
ASC have been validated to possess consistent osteogenic potential41-43, ASC still contain 
significant drawbacks that hinder their clinical application26. For instance, much like in BMSC, 
ASC require in vitro cultivation which has been previously been observed to decrease stemness, 
self-renewal, and multipotency44. In select cases, culture of ASC has been observed to result in 
genomic instability and in-turn malignant transformation45. With these significant drawbacks 
present in BMSC, ASC, and other stem cell populations that were not highlighted herein, there 
exists a clinical need for a reliable and abundant source of MSC that do not require an extensive 
isolation protocol. 
Perivascular stem cells (PSC) are a homogenous stem cell population that are isolated 
utilizing fluorescence-activated cell sorting (FACS) from the aforementioned stromal vascular 
fraction (SVF), a collagenase-treated lipoaspirate (isolation procedure outlined in Figure 1). What 
differentiates PSC from ASC (adipose-derived stem cells) is the fact that these cells are identified 
by their cell surface markers using FACS and include pericytes from microvessels and capillaries 
(which are CD34-, CD146+, CD45-), and adventitial cells from larger arteries and veins (which 
are CD34+, CD146-, CD45-)46. This isolation protocol ensures minimal manipulation and 
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passages in vitro, decreasing the risk of mutation and genetic instability. The composition of 
pericytes and adventitial cells together, termed PSC, exhibit characteristic surface markers of 
multilineage potential that has been previously demonstrated in various studies by our group 47-51. 
The osteogenic potential of PSC have extensively been verified in several small and large 
animal studies. First, human adipose-derived PSC were shown to promote bone formation in an 
ectopic muscle pouch-implantation model, far superior to that of patient-matched, SVF52, 53. This 
increase in osteogenic potential was paralleled with an increase in vascular infiltration54. In a 
subsequent study, PSC, from various patient demographics (gender, age, body mass index(BMI)), 
were observed to successfully recover mice that were afflicted with a critical-size calvarial defect. 
As such, it was concluded that PSC possess immense osteogenic potential, irrespective of patient 
age, gender or BMI55. Contingent on these findings, a study was performed to evaluate the dose-
dependent effect of human PSC (hPSC) implantation in athymic rats and the success on cervical 
spinal fusion. It was observed that although all samples treated with hPSC, irrespective of dose, 
were capable of inducing successful boney bridging, animals treated with a higher concentration 
of hPSC were observed to possess more bone and of higher density56. Importantly, no pathologic 
findings were observed in any samples in the aforementioned studies. 
The mechanism by which PSC induced bone formation, however remains largely 
unelucidated. To investigate whether the bone formed was by direct differentiate of PSC, much 
like most MSC, or via recruitment of host osteoprogenitor cells, human PSC were implanted in 
athymic rats and the newly formed bone was assayed for expression human and/or rat major 
histocompatibility complex (MHC). Subsequently, RNA sequencing (RNASeq) was performed to 
assess differential expression of secreted Wnt-related molecules between PSC and unpurified SVF. 
Loss of function and gain of function assays were next performed to further understand the 
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mechanism by which PSC induce optimized bone formation. In aggregate, our findings suggest 
that perivascular stem cells are a potent autologous stem cell population that are ample in supply, 
capable of promoting robust bone formation via, primarily paracrine-mediated, osteoprogenitor 
recruitment by means of Wnt-related secretory molecules, WISP1 and Wnt16. 
 
Results 
Direct Differentiation vs Paracrine-Mediated Recruitment of Osteoprogenitor Cells 
 As it has been well documented that PSC harness the potential to induce bone formation in 
several loci and models, we first sought to investigate whether this bone formation was primarily 
through direct differentiation of implanted PSC or through recruitment of host mesenchymal stem 
cells. To answer this preliminary question, athymic rats underwent spinal fusion procedure 
whereby they were implanted with increasing doses of patient-matched human PSC (hPSC). 
Sections of the boney bridges were stained using immunohistochemistry for anti-human MHC and 
anti-rat MHC to assess whether the newly formed bone was of donor- or host- origin (Figure 2A). 
Qualitative observation of low magnification sections revealed an increased intensity stain for host 
(rMHC-positive) cells, both in the osteocytes found in the newly formed bone, as well as the bone-
lining osteoblasts when compared to donor (hMHC-positive) cells. As anticipated, with the 
increasing dose of human PSC, a correlate existed with an increased number of human-derived 
osteoblasts (Figure 2B). Of interest, however, was the significantly higher amount of host 
(rMHC+) bone-lining osteoblasts, suggesting the majority of bone-lining osteoblasts were of host-
descent. Similar findings were observed when newly formed osteocytes were quantified (Figure 
2C). Again, a dose-dependent increase was observed for both human- and rat-specific osteocytes, 
however, a majority of these osteocytes were indeed of host origin. These findings suggest that 
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PSC mediate bone formation via, primarily, a paracrine-mediated mechanism, although some PSC 
undergo direct differentiation.  
 
Activation of Wnt signaling during hPSC Osteogenic Differentiation 
Next, we sought to investigate the process of human PSC osteogenic differentiation and its 
correlate with changes in Wnt signaling over time. As anticipated, when hPSC were cultured in 
osteogenic medium, a steady and significant increase was observed in osteogenic markers, 
Osteocalcin (OCN) and master osteogenic factor, Runt-related transcription factor 2 (Runx2) 
(Figure 3A). Expression of gene markers associated with Wnt signaling was observed to increase 
early in osteogenic differentiation with Axin2 and cMYC peaking on days 6 and 3, respectively 
(Figure 3B). The nuclear accumulation of β-catenin, however, steadily increased throughout the 
observation period with a statistically significant increase noted as early as day 1 (Figure 3C). In 
aggregate, these data suggest that PSC, under osteogenic conditions, demonstrate increased 
expression of pro-osteogenic molecules and that these changes are at least partially due to Wnt 
signaling, during early differentiation. 
 
WISP-1 and Wnt16 transcripts are upregulated in PSC 
Next RNA Sequencing (RNASeq) was next performed to compare transcript expression 
levels between PSC and unpurified SVF. Four SVF and PSC populations, collected from the same 
four patient samples, were prepared for RNASeq analysis freshly after isolation. Focus was placed 
on secreted molecules, known to be associated with Wnt signaling associated genes. It was 
observed that WNT1-inducible-signaling pathway protein (WISP)-1 and Wnt16 were upregulated 
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in PSC by 72.0 fold and 21.0 fold, respectively. As such, these two molecules were subjects of 
future study to investigate their role in the mechanism of PSC-mediate osteogenesis. 
 
Role of WISP-1 in PSC osteogenesis 
To evaluate the role of WISP-1 on PSC osteogenesis, both gain-of-function and loss-of-
function assays were performed. First, WISP-1 overexpression was assayed by two modalities: 1] 
plasmid overexpression of WISP-1 (Figure 4A-C) and 2] supplementation with recombinant 
WISP-1 protein(Figure 4D-F). Plasmid success was assessed by qRT-PCR, and it was observed 
that PSC, transfected with the WISP-1 plasmid, possessed a 11.9-fold increase WISP-1 expression 
(Figure 4A). In PSC transfected with this plasmid, an increase was observed in osteogenic markers 
RUNX2 and OCN (Figure 4B,C). Further, in hPSC treated with recombinant WISP-1, an increase 
in RUNX2 and OCN expression was also observed (Figure 4D,E). Previous studies have 
demonstrated that WISP-1 is a potent inhibitor of SOST (an inhibitor of both the Wnt canonical 
pathway and BMP-2 pathway)57, 58. SOST operates by binding and inhibiting BMP2 signal 
transduction59, and by binding to LRP5/6, inhibiting canonical Wnt signaling57. Therefore, the 
upregulation of WISP-1 was hypothesized to potentiate osteogenesis by promoting two major 
osteogenic signal transduction pathways: 1] canonical Wnt pathway and 2] BMP-2 pathway. To 
evaluate the effect on the BMP-2 signaling, PSC were co-treated with WISP-1 and BMP2. As 
hypothesized, a synergistic increase in ALP (alkaline phosphatase) expression was observed 
(Figure 4F).  
Next, to investigate the necessity of WISP-1 on the osteogenic potential of PSC, WISP-1 
was knocked down utilizing WISP-1 siRNA. A single siRNA sequence was selected that provided 
>90% gene silencing of WISP-1 in human PSC, assessed by qRT-PCR (Figure 5A). This 
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knockdown of WISP-1 significantly decreased markers of osteogenesis in PSC, as observed by a 
58% decrease in RUNX2 transcripts levels at 3 days post-KO (Figure 5B). Similarly, with WISP-
1 knockout, the expression of alkaline phosphatase (ALP), a glycoprotein found on the surface of 
osteoblasts, which reflects bone metabolism, was significantly decreased (40% decrease) (Figure 
5C). Additionally, alizarin red and alkaline phosphatase staining, both markers for osteogenesis, 
were observed to be markedly decreased when PSC were treated with WISP-1 siRNA (Figure 5D). 
Lastly, we sought to evaluate the effect of recombinant BMP-2 protein on PSC treated with WISP-
1 siRNA (Figure 5E,F). Although BMP-2 protein did slightly improve RUNX2 and ALP expression 
in WISP-1 knockout cells, this increase was modest compared to wildtype PSC, treated with BMP2 
only. These data that WISP-1 knockdown significantly inhibits osteogenic marker expression, as 
confirmed by a decrease in RUNX2 and ALP, via indirect activation of SOST. 
Taken together, WISP-1 is a critical secretory molecule that facilitates the osteogenic 
potential of PSC via activation of the canonical Wnt and BMP signaling pathways, through the 
inhibition of SOST. Loss of function studies reveal that WISP-1 silencing inhibits bone formation, 
while overexpression of WISP-1 activates osteogenesis. 
 
Role of WNT16 in PSC osteogenesis 
 As Wnt16 was upregulated by 21-fold in PSC, when compared to SVF, the role of Wnt16 
in PSC osteogenesis was next evaluated. When WNT16 levels were assessed after PSC were 
cultured in osteogenic differentiation medium, it was observed that WNT16 expression 
significantly increased by day 3, and steadily decreased back to baseline by day 9 (Figure 6A), 
suggesting WNT16 plays a role in early osteogenic differentiation. Previous studies have 
established WNT16 as a known a mixed canonical and noncanonical ligand suggesting that it 
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conditionally activates two separate signal transduction cascades. Moreover, Ozeki et al reported 
that BMP-2 promotes WNT16 binding to the Fzd2/LRP5 pathway, further activating the canonical 
pathway via accumulation of cellular β-catenin60. Herein, we observed an early activation of the 
canonical pathway with Wnt16 treatment, followed by an inactivation of the canonical pathway 
and activation of the non-canonical pathway. When PSC were co-cultured with recombinant 
WNT16, an early increase in the markers of the canonical Wnt pathway (AXIN2 and cMYC) was 
observed at day 3(Figure 6B). However, beginning on day 6, these levels were significantly 
decreased compared to control suggesting inhibition of the canonical Wnt pathway. This was 
paralleled with an increase in osteogenic markers RUNX2, ALP, and OCN, suggesting activation 
of the noncanonical pathway and promotion of osteogenic differentiation (Figure 6C). Moreover, 
there was a significant increase in bone nodule formation when PSC were cultured with 
recombinant WNT16 protein (Figure 6D). This increase in osteogenic differentiation was 
accompanied by an increase of noncanonical signaling molecule, JNK activity in WNT16-treated 
PSC, as shown by p46 and p54 phosphorylation assessed by western blot (Figure 6E). 
To further confirm the importance of WNT16 in the osteogenic effect of PSC, knockdown 
was performed using WNT16 siRNA (Figure 7). qRT-PCR confirmed the knockdown efficiency 
of WNT16 mRNA at 60% (Figure 7A). This decrease in Wnt16 expression was correlated with a 
significant decrease in osteogenic markers RUNX2, ALP and OCN by 43%, 60% and 60%, 
respectively (Figure 7B). Further examination by ALP and AR staining confirmed reduced 
osteogenic differentiation with WNT16 siRNA (Figures 7C,D). ALP staining was reduced by 
64.1% (Figure 7C), while bone nodule deposition as examined by AR staining was reduced by 
70.0% (Figure 7D). These data suggest that Wnt16 plays an important role in the commitment and 
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differentiation of PSC down the osteogenic lineage, and is necessary for PSC to elicit their 
osteogenic effect. 
 
Discussion 
As previously mentioned the number of orthopaedic procedures performed per annum is 
steadily increasing however the gold standard of treatment, autologous bone grafting, has remained 
stagnant. Unfortunately, there exists a number of drawbacks in the use of autologous bone grafting, 
including donor site morbidity, increased risk of infection, limited supply, and increased 
intraoperative time. With the utilization of PSC, we can dramatically decrease the surgical time by 
ease of isolation and purification, and the donor site morbidity due to the relative ease of the 
liposuction procedure. Until present, the modality by which PSC induced bone formation, 
however, remained unclear. Herein, we demonstrated that PSC primarily induce bone via 
paracrine-mediated recruitment and induction of local osteoprogenitor, mesenchymal stem cells. 
This recruitment and differentiation is due to secretory Wnt-related molecules, of which WISP-1 
and Wnt16 were significantly upregulated in PSC compared to their unpurified stromal vascular 
fraction. Upregulation of WISP-1 and Wnt16 in PSC induced improved bone formation, whereby, 
inactivation demonstrated a significant decrease in osteogenic potential. This osteogenic 
differentiation was due to activation of both the BMP pathway, as well as the Wnt β-catenin 
pathways (schematized in Figure 8).  
 Previous studies have confirmed the role of WISP-1 in both BMP-2 and Wnt canonical 
pathways. As a member of the CCN (connective tissue growth factor, Cyr61, NOV) family of 
growth factors, WISP-1 is involved in skeletogenesis and bone healing61. In a fracture repair 
11 
 
 
model, WISP-1 expression has been observed to increase, spatiotemporally, recapitulating skeletal 
development62. Within BMP-2 signaling, WISP-1 serves two roles. First, it serves as a potent 
inhibitor of SOST57, 58, a protein that competes with BMP receptors for BMP-2 binding63. 
Therefore, by increasing the amount of readily available BMP-2 to bind to the BMP receptors by 
binding and inhibiting SOST, WISP-1 promotes BMP signaling. Second, WISP-1 has been shown 
to potentiate BMP signaling by binding directly to BMP-2 and increasing its osteogenic effect, in 
a dose-dependent manner64. Therefore by means of this dual-effect of WISP-1, there is a net 
increase in the amount of BMP-2 available, and the available BMP-2 can functionally interact with 
WISP-1, enhancing the efficacy of BMP-2. 
 WISP-1 also plays a role in the activation of the canonical Wnt pathway. WISP-1, as 
previously mentioned, binds to SOST57, 58 which is an inhibitor of the canonical Wnt pathway65. 
By binding to the extracellular domain of Wnt co-receptors LRP5 and LRP6, SOST disrupts the 
interaction between the Wnt-induced Frizzled (Fzd) and LRP complex and therefore attenuates 
canonical Wnt signaling65. Thus, an inactivation of SOST via binding of WISP-1, results in the 
interaction of Fzd and LRP proteins subsequent to Wnt ligand binding, and ultimately 
accumulation of nuclear β-catenin resulting in osteogenic differentiation66. In aggregate, WISP-1 
plays several roles in the osteogenic effect of PSC. By simulating natural skeletogenesis as a 
member of the CCN family, WISP-1 promotes BMP-2 signaling and inactivates SOST, thereby 
un-inhibiting the BMP-2 and canonical Wnt pathways. 
 As a generally accepted mixed canonical and noncanonical Wnt ligand, WNT16 plays a 
complex role in the osteogenic differentiation of PSC67. First, as a canonical ligand, previous 
authors demonstrated that in WNT16-deficient mice, a decrease in periosteal bone formation and 
mineral apposition was observed. These findings are in conjunction with a significant decrease in 
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canonical markers β-catenin and Axin2, but not noncanonical markers Nfatc1, Tnnt2, and JNK68. 
Conversely, other authors have reported that Wnt16 serves as a protector from over activation of 
the canonical pathway, thereby supporting homeostasis. In a study by Nalesso, et al. WNT16 
reduced the capacity of WNT3A, potent canonical-activator, to activate the canonical WNT 
pathway69. Herein, we observe both phenomenon. Early treatment with WNT16 resulted in a 
statistically significant increase in canonical marker, AXIN2, however, this expression decreased 
by day 6 (see again Figure 6B). Furthermore, we observed that WNT16 treatment resulted in an 
increase in downstream noncanonical protein, JNK, over time. Therefore, contingent on previous 
studies and the data herein, there exists a high dependence on the model system and culture 
conditions on the role of Wnt16. Nonetheless, it plays a critical role, in conjunction with WISP-1 
in the commitment of mesenchymal stem cell down the osteogenic fate and a paramount role in 
PSC-mediated osteogenic differentiation. 
 
Conclusion & Future Direction 
Our findings partially elucidate the mechanism whereby perivascular stem cells induce 
their robust osteogenic effect. We have resolved that human PSC operate via a primarily paracrine-
mediated mechanism, although some direct differentiation does indeed occur. By means of 
RNASeq, WISP-1 and Wnt16 were discovered to be upregulated secretory, Wnt-relatated, 
molecules in PSC. Upon further investigation, their roles were understood in activation of the 
osteogenic pathway of BMP-2, as well as both the canonical and noncanonical Wnt pathways. In 
aggregate, both WISP-1 and WNT16 were confirmed to play an important and necessary role in 
the commitment and differentiation of PSC down an osteogenic lineage. 
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 Future studies should not only further investigate the mechanism of hPSC, however, should 
expand upon optimizing their isolation protocol. Although FACS is far superior in comparison to 
culture, in respect to speed and efficacy of isolation, recently investigators have utilized magnetics 
via MACS (magnetic activated cell sorting) to isolate mesenchymal stem cells with success70. 
Therefore, moving forward, studies should be performed to both understand the mechanism of 
hPSC, improving their isolation, and confirming their safety profile to begin translation into the 
clinical setting.  
 
Materials & Methods 
Immunohistochemistry of Rat Spinal Fusion Samples 
After spines were harvested from previous study56, samples were decalcified using 19% 
EDTA and embedded in paraffin. Immunohistochemical staining was performed with primary 
antibodies against both human and rat major histocompatibility complex (MHC) class I antigens 
(Santa Cruz Biotechnology using the ABC (Vector Laboratories, Burlingame, 
CA, http://www.vectorlabs.com) method. Immunohistochemistry was performed after paraffin 
slices were deparaffinized, dehydrated, rinsed, and incubated with 3% H2O2 for 20 minutes. All 
sections were then blocked with 0.1% bovine serum albumin in PBS for 1 hour. At a dilution of 
1:100, primary antibodies were added to each section and incubated at 37°C for 1 hour or overnight 
at 4°C. Images were obtained on an Olympus (Center Valley, 
PA, http://www.olympusamerica.com) BX51 fluorescence microscope. Species specific 
osteoblast and osteocyte quantifications were performed for positive staining of MHC at 40x 
magnification using Photoshop (Adobe Systems Inc., San Jose, CA, http://www.adobe.com). 
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PSC Isolation  
PSC were isolated from human subcutaneous adipose tissue via FACS. Lipoaspirate was 
stored for no more than 48 h at 4°C before processing. Subsequently, collagenase digestion was 
performed, yielding the human SVF (stromal vascular fraction. Briefly, lipoaspirate was diluted 
with an equal volume of phosphate-buffered saline (PBS) before digestion with Dulbecco’s 
modified Eagle’s medium (DMEM) containing 3.5% bovine serum albumin (Sigma-Aldrich, St. 
Louis, MO) and 1 mg/mL type II collagenase for 70 min under agitation at 37°C. Adipocytes were 
next separated and removed by centrifugation. The pellet was then resuspended in red cell lysis 
buffer (155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA) and incubated for 10 min at room 
temperature. After centrifugation, pellets were again resuspended in PBS and filtered at 70 mm. 
The resulting hSVF was further processed for cell sorting (to isolate PSC). A subset of this SVF 
was shipped for RNA Sequencing with patient-matched PSC. hSVF was incubated with a mixture 
of the following directly conjugated antibodies: anti-CD34- phycoerythrin (1:100; Dako, Glostrup, 
Denmark), anti- CD45-allophycocyanin (1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 
and anti-CD146-fluorescein isothiocyanate (1:100; AbD Serotec, Raleigh, NC). All incubations 
were performed at 4°C for 15min in the dark. Before sorting, 4’,6-diamidino-2-phenylindole 
(DAPI; 1:1000; Invitrogen, Carlsbad, CA) was added for dead cell exclusion; the solution was 
then passed through a 70-mm cell filter and then run on FACSAria cell sorter (BD Bio- sciences, 
San Diego, CA). Sorted cells were plated for in vitro studies. In this manner, distinct microvessel 
pericytes (CD34-, CD146+, and CD45-) and adventitial cells (CD34+, CD146-, and CD45-) were 
isolated and combined to constitute the PSC population. Cells were cultured at 37°C in a 
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humidified atmosphere. The expansion of cells was performed in DMEM, 20% fetal bovine serum 
(FBS), and 1% penicillin/streptomycin. Medium was changed every 3 days. 
 
RNA Sequencing 
Patient matched samples of SVF and purified PSC were next isolated to single cell lysates 
in 96-well plates. Plates were stored at -80°C and shipped to Fluidigm Corporation (South San 
Francisco) on dry ice for RNASeq to be performed71, on patient-matched SVF and PSC samples. 
Transcripts of interest were secreted, Wnt-related molecules. 
 
Assays performed in growth medium 
PSC were seeded in six-well plates at a density of 1x105 cells/well and allowed to adhere 
overnight. Cells were cultured in DMEM +10% FBS +1% penicillin/ streptomycin and treated 
with recombinant WISP-1 (200ng/mL), BMP-2 (50ng/mL), or WNT16 (50ng/mL) for 6 days, at 
which time RNA isolation was performed.  
 
Osteogenic differentiation assays 
Assays for PSC differentiation were adapted from prior publications72-74. The osteogenic 
differentiation medium (ODM) was constituted with 10mM β-glycerophosphate and 50 mM 
ascorbic acid in DMEM +20% FBS. Medium supplemented with Wnt ligand was changed q3d of 
differentiation.  
Alkaline phosphatase (ALP) staining was performed using the leukocyte alkaline 
phosphatase kit (Sigma- Aldrich). In brief, cells were seeded in 24-well plates (density of 1x104 
cells/well). Cells were cultured under osteogenic differentiation conditions for 12 days prior to 
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staining. Cells were then washed with PBS and fixed with formalin for 10min. Following fixation, 
cells were stained using leukocyte alkaline phosphatase kit (Sigma-Aldrich) according to the 
manufacturer’s protocol. Cells were incubated in ALP stain for 15 min at 37°C and subsequently 
washed with PBS. Cells were allowed to dry and pictures were taken at 100x magnification using 
the Olympus IX71 inverted system microscope (Olympus, Cypress, CA). Relative staining was 
quantified using Adobe Photoshop CC2015.  
For the detection of mineralization, cells were seeded in growth medium in 24-well plates 
(density of 1x104 cells/well). After cell seeding for twenty-four hours, the basal medium was 
replaced with ODM containing WISP-1 or WNT16 in triplicate for 12 days (200ng/mL or 
50ng/mL, respectively). Cells were washed with PBS and fixed with 4% paraformaldehyde. 
Subsequent to fixation, cells were stained with 2% alizarin red (Sigma-Aldrich) at room 
temperature for 15 min, washed with deionized water, and allowed to dry. Photographs were taken 
at 100x magnification using the Olympus IX71 inverted system microscope (Olympus). To 
quantify bone nodule deposition, 10% v/v acetic acid was added and cells were incubated at room 
temperature for 30 min while shaking. Cells were then scraped from the wells and vortexed for 
30s. Next, cells were overlaid with mineral oil and heated to 85°C for 10 min. Cells were briefly 
cooled on ice for 5 min and then centrifuged at 20,000 g for 15 min. Ten percent ammonium 
hydroxide was added to adjust the pH to between 4.1 and 4.15. Absorbance was measured in 
triplicate at 405nm in 96-well plates using Epoch microspectrophotometer (Bio-Tek, Winooski, 
VT).  
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RNA Isolation and qRT-PCR 
Gene expression was assayed by quantitative real-time polymerase chain reaction (RT-
PCR), based on previous publications72, 74, 75.  Time points for specific gene expression include 3, 
6, 9, and 12 days of osteogenic differentiation. In brief, total RNA was extracted using the RNeasy 
Kit (Qiagen, Santa Clarita, CA). One microgram of total RNA from each sample was subjected to 
first-strand complementary deoxyribonucleic acid (cDNA) synthesis using the SuperScript III 
Reverse-Transcriptase Kit (Life Technologies) to a final volume of 20 mL The reverse 
transcription reaction was performed at 65°C for 5 min, followed by 50°C for 50 min and 85°C 
for 5 min. For qRT-PCR, the reactions were performed using 2xSYBR green RT-PCR master mix 
and an ABI PRISM 7300 qRT-PCR system instrument (Applied Biosystems, Foster City, CA). 
qRT-PCR was performed using 96-well optical plates at 95°C for 10 min, followed by 40 cycles 
at 95°C for 15 s and at 60°C for 60 s. The relative quantification of gene expression was performed 
using a Comparative CT method according to the manufacturer’s protocol and was normalized to 
the expression levels of the housekeeping gene, GAPDH or ACTB, in each sample.  
 
Whole Protein Extraction and Western Blot Analysis 
Protein extraction and western blot analysis were adapted from our prior publications72, 74. 
Western blot analysis was performed using antibodies against nuclear β-catenin, JNK (1:1000, 
Cell Signaling Technologies, Danvers. MA), GAPDH, or H3 (Santa Cruz Biotechnology). To 
measure cytoplasmic and nuclear β-catenin protein levels, cells were seeded in six-well plates at a 
density of 4x104 cells/well. After attachment, basal medium was replaced with starvation medium 
containing DMEM + 1% FBS for 16 h. Medium was then replaced with ODM for up to 12 days. 
Cells were then washed with PBS and re- suspended in 150 mL of radioimmunoprecipitation assay 
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buffer (RIPA) (Thermo Fisher Scientific) with 100· Halt protease/phosphatase inhibitor cocktail 
(Life Technologies) added. Nuclear and cytoplasmic protein was isolated using the NE-PER 
Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific).  
JNK quantifications were performed by initially seeding cells in six-well plates at a density 
of 4x104 cells/well. After attachment, basal medium was replaced with starvation medium 
containing DMEM + 1% FBS for 16h. Cells were then treated with WNT16 for 15, 30, 60, and 
120 min in starvation medium and were resuspended in 150 mL of RIPA buffer (Thermo Fisher 
Scientific) with Halt protease/phos- phatase inhibitor cocktail (Life Technologies) added. For 
western blot analysis, 30 mg of total protein combined with 5· reducing loading buffer (Thermo 
Fisher Scientific) was boiled for 5 min, separated by SDS-PAGE, and electrotransferred to a 
nitrocellulose membrane (GE Healthcare, Piscataway, NJ) at 200 V for 1 h at 4°C. The membrane 
was blocked for 1 h in Superblock (TBS) Blocking Buffer (nuclear β-catenin, cytoplasmic β-
catenin, ACTB, GAPDH, nuclear H3) (Thermo Fisher Scientific) or 5% BSA (JNK).  
Western blot analysis was performed using antibodies against nuclear β-catenin (Cell 
Signaling Technologies), GAPDH (Santa Cruz Biotechnology), H3, or JNK(Cell Signaling 
Technologies) at dilutions of 1:1000 over- night at 4°C, then washed with TBST, and incubated in 
a secondary antibody (Abcam, Cambridge, MA) at 1:10,000 dilution in blocking buffer at room 
temperature for 1h. Following incubation, the membranes were washed three times with TBST 
and proteins were visualized using the Peirce enhanced chemiluminescence western blotting 
substrate (Thermo Fisher Scientific) as per the manufacturer’s instructions. Quantitation of 
western blot intensity was performed using NIH ImageJ.  
 
19 
 
 
Small interfering RNA and transfection 
Knockdown of WISP-1 and WNT16 were performed using Silencer Select chemically synthesized 
small interfering RNA (siRNA) (Thermo Fisher Scientific). Cells were seeded in six-well plates 
(density of 4x104). At 50% confluence, basal medium was replaced with antibiotic-free basal 
medium. Transfection was performed using X-tremeGENE siRNA Transfection Reagent (Sigma- 
Aldrich) and 150 pM WISP-1 siRNA, 150 pM WNT16 siRNA or scrambled siRNA diluted in 
minimal essential medium (Opti-MEM). For the confirmation of siRNA efficiency, six hours after 
transfection, medium was replaced with basal medium and the efficiency of the knockdown was 
validated using qRT-PCR. For alizarin red (AR) and ALP staining, six hours after transfection, 
medium was replaced with ODM and cells were cultured under osteogenic differentiation 
conditions for 12 days.  
 
Statistical analysis.  
All results are expressed as mean–standard deviation (SD). Statistical analyses were 
performed using the SPSS16.0 software. Normal quantile plots were examined to confirm the data 
followed the normal Gaussian distribution, allowing the use of parametric methods. Student’s t 
test was used for two-group comparisons, and one-way ANOVA test was used for comparisons of 
three or more groups, followed by Tukey’s post hoc test. Differences were considered significant 
when p < 0.05.  
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Figures 
 
 
 
Figure 1. Isolation Protocol of PSC. Perivascular stem cells (PSC) are comprised of two distinct 
MSC populations, consisting of pericytes which are found on the periphery of microvessels and 
adventitial cells which are found on larger vessels. Subsequent to liposuction procedure, a 
lipoaspirate is collected and treated with collagenase. This collagenase-treated sample yields the 
stromal vascular fraction (SVF). To purify PSC, SVF is sorted for negative expression of CD45, 
CD31, and differential expression of CD146 and CD34.  
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Figure 2. Osteoprogenitor origin of newly formed bone cells. (A) Immunohistochemistry was 
performed against human and rat MHC on samples of rat vertebrae treated with increasing dosages 
of human PSC. Quantifications were performed at 40x magnification for quantity of species-
specific (B) osteoblasts and (C) osteocytes per high powered field. Abbreviations: hMHC, human-
specific major histocompatibility complex; HPF, higher power field; hPSC, human perivascular 
stem cells; MHC, major histocompatibility complex; Ob, osteoblasts; Ot, osteocytes; rMHC, rat-
specific major histocompatibility complex. *p≤0.05 compared to with rat-specific control values, 
**p≤0.01 compared to with rat-specific control values, ##p≤0.01 compared to human-specific 
control values. Adapted from Chung et al56, with permission. 
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Figure 3. Regulation of Wnt signaling during hPSC osteogenic differentiation. (A) mRNA 
transcript levels of hPSC osteogenic markers OCN and RUNX2 were calculated over 12 days. (B) 
Canonical Wnt-related transcript levels increased early during osteogenic differentiation and 
began decreasing after day 6. (C) Intracellular β-catenin was next quantified and cytoplasmic β-
catenin spiked at day 1 and began decreasing as nuclear β-catenin consistently increased, 
consistent with activation of the canonical Wnt pathway. Abbreviations: OCN, Osteocalcin; 
RUNX2, Runt Related Transcription Factor 2. *p≤0.05 compared to respective control. **p≤0.01 
compared to respective control. Adapted from Shen et al74, with permission. 
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Figure 4. WISP-1 upregulation increases osteogenic differentiation. The effect WISP-1 
overexpression by either (A-C) plasmid or (D-F) recombinant protein was next assessed. (A) 
Plasmid transfection demonstrated a near 12-fold increase in WISP-1 expression. This increase in 
WISP-1 expression was correlated with a significant increase in expression of osteogenic markers 
(B) RUNX2 and (C) OCN. (D,E) Further, when PSC were treated with recombinant WISP-1 
protein, an increase in RUNX2 and OCN expression was observed. (F) Individual treatment with 
WISP-1 and BMP-2 both increased ALP staining, however co-administration demonstrated a 
statistically significant and synergistic increase on ALP expression. Abbreviations: WISP-1, 
WNT1 Inducible Signaling Pathway Protein 1; RUNX2, Runt Related Transcription Factor 2; 
OCN, Osteocalcin. ALP, Alkaline Phosphatase. BMP, Bone Morphogenetic Protein. *p≤0.05 
compared to respective control. **p≤0.05 compared to respective control. 
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Figure 5. WISP-1 downregulation inhibits osteogenic differentiation. siRNA was constructed 
against WISP-1. (A) Knockdown was confirmed with >90% gene silencing of WISP-1. This 
downregulation was coincident with a decrease in osteogenic markers (B) RUNX2 and (C) ALP. 
(D) ALP and Alizarin red staining of bone nodules showed a decrease stain intensity in WISP-1 
knockdown samples. (E,F) Osteogenic markers, RUNX2 and ALP, expression was next evaluated. 
Supplementation with BMP2 increased RUNX2 and ALP expression, while WISP-1 siRNA 
inhibited expression. The osteogenic effect of BMP2 was inhibited when cells we co-exposed to 
BMP2 and WISP-1 siRNA. Abbreviations: WISP-1, WNT1 Inducible Signaling Pathway Protein 
1; RUNX2, Runt Related Transcription Factor 2; ALP, Alkaline Phosphatase, BMP2, Bone 
Morphogenetic Protein 2; siRNA, small interfering ribonucleic acid. *p≤0.05 compared to 
respective control. **p≤0.01 compared to respective control. Adapted from Shen et al74, with 
permission. 
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Figure 6. WNT16 and Wnt signaling. (A) hPSC cultured in osteogenic differentiation medium 
demonstrate a significant increase in WNT16 early during osteogenic differentiation which 
significantly and steadily decreases after day 3. (B) hPSC treated with recombinant WNT16 
protein demonstrate an early increase in canonical Wnt signaling transcripts AXIN2 and cMYC 
which decreased demonstrating an early activation and subsequent inactivation of the canonical 
Wnt pathway. (C) Osteogenic markers RUNX2, ALP, and OCN were quantified using qRT-PCR 
and demonstrated a significant increase when hPSC were treated with recombinant WNT16 
protein. (D) Bone nodule formation in hPSC were next stained with Alizarin red and quantified 
for stain intensity. (E) Western blots and densiometry demonstrated that with Wnt16 treatment, a 
steady and significant increase in noncanonical JNK was observed. Abbreviations: RUNX2, Runt 
Related Transcription Factor 2; ALP, Alkaline Phosphatase; OCN, Osteocalcin; AR, Alizarin Red; 
JNK, Jun N-terminal Kinase; ACTB, Actin beta; qRT-PCR, Quantitative Real Time Polymerase 
Chain Reaction. *p≤0.05 compared to respective control. **p≤0.01 compared to respective 
control. Adapted from Shen et al74, with permission. 
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Figure 7. WNT16 downregulation inhibits osteogenic differentiation. (A) Wnt16 siRNA was 
successfully utilized to knockdown WNT16 expression (60% decrease in expression confirmed by 
qRT-PCR. (B) This decrease in WNT16 resulted in decrease in osteogenic markers RUNX2, ALP, 
and OCN at 3 days post-transfection. (C) ALP staining was performed at 12 days after transfection 
and a significant decrease in staining intensity was observed. (D) AR staining performed on bone 
nodule deposition was subsequently quantified and a reduction was observed in WNT16 siRNA-
treated cells. Abbreviations: RUNX2, Runt Related Transcription Factor 2; ALP, Alkaline 
Phosphatase; OCN, Osteocalcin; AR, Alizarin Red; siRNA, small interfering ribonucleic acid; 
qRT-PCR, Quantitative Real Time Polymerase Chain Reaction. Black scale bar = 200 µm 
**p≤0.01 compared to respective control. Adapted from Shen et al74, with permission. 
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Figure 8. Schematic representation of the hypothesized role of WNT16 & WISP-1 in PSC 
osteogenic differentiation.
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